Cytosorbents (NASDAQ:CTSO) Now Covered by StockNews.com

StockNews.com began coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research note published on Wednesday. The firm issued a hold rating on the medical research company’s stock.

Separately, D. Boral Capital reiterated a “buy” rating and issued a $10.00 price objective on shares of Cytosorbents in a report on Tuesday, February 25th. Two analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $4.67.

Cytosorbents Stock Performance

Shares of NASDAQ CTSO opened at $1.00 on Wednesday. Cytosorbents has a 52 week low of $0.70 and a 52 week high of $1.61. The stock has a market capitalization of $54.68 million, a PE ratio of -2.78 and a beta of 0.78. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.58 and a current ratio of 1.97. The stock has a 50 day moving average price of $1.07 and a 200 day moving average price of $1.05.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Renaissance Technologies LLC lifted its holdings in Cytosorbents by 10.6% in the fourth quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company’s stock valued at $80,000 after buying an additional 8,400 shares during the period. Northern Trust Corp grew its holdings in shares of Cytosorbents by 22.3% during the fourth quarter. Northern Trust Corp now owns 91,560 shares of the medical research company’s stock valued at $83,000 after buying an additional 16,701 shares during the last quarter. Skylands Capital LLC lifted its position in Cytosorbents by 1.0% in the 4th quarter. Skylands Capital LLC now owns 2,781,622 shares of the medical research company’s stock valued at $2,531,000 after acquiring an additional 26,195 shares in the last quarter. Geode Capital Management LLC boosted its stake in Cytosorbents by 7.5% during the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after purchasing an additional 32,415 shares during the last quarter. Finally, Millennium Management LLC purchased a new stake in shares of Cytosorbents in the fourth quarter worth approximately $30,000. Institutional investors and hedge funds own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.